Stock Analysis on Net

Celgene Corp. (NASDAQ:CELG)

$22.49

This company has been moved to the archive! The financial data has not been updated since October 31, 2019.

Return on Assets (ROA)
since 2005

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Celgene Corp., ROA, long-term trends, calculation

Microsoft Excel

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$ in millions


The financial data indicates several notable trends over the 14-year period analyzed. Net income attributable to the company displays significant volatility, including a substantial loss in 2008 followed by a strong recovery and consistent growth. Total assets show a steady overall increase, reflecting expansion or accumulation of resources. The Return on Assets (ROA) fluctuates considerably, aligning with the variations in net income, and demonstrates periods of both decline and improvement.

Net Income (Loss) Attributable to the Company
The net income began at a moderate level of $64 million in 2005 and showed a gradual increase through 2007, reaching $226 million. However, 2008 experienced a marked downturn with a significant loss of $1,534 million, indicating a particularly challenging year. From 2009 onward, net income rebounded strongly, hitting $777 million, then progressively rising in the following years. By 2018, net income had increased substantially to $4,046 million, representing robust profitability and growth. Despite some fluctuations, the trend from 2009 to 2018 is one of consistent income growth.
Total Assets
Total assets have consistently increased throughout the period. Starting from $1,247 million in 2005, assets expanded sharply to $10,177 million by 2010. While some minor fluctuations occurred in subsequent years, the general trajectory remained upward, culminating in $35,480 million by 2018. This trend suggests a sustained strategy of asset accumulation or investment, potentially supporting operational scaling or acquisitions.
Return on Assets (ROA)
The ROA metric exhibited notable variability, reflective of changes in net income relative to total assets. The ratio began at 5.11% in 2005, dipped to a low of 2.52% in 2006, then rose to 6.27% in 2007 before plunging dramatically to -34.5% in 2008, coinciding with the loss year. From 2009 forward, the ROA rebounded to 14.41%, then generally stabilized, fluctuating between approximately 5.92% and 13.17% in the following years. The upward trend toward the end of the period, reaching 11.4% in 2018, indicates improved efficiency in generating earnings from assets after the 2008 downturn.

Comparison to Competitors

Celgene Corp., ROA, long-term trends, comparison to competitors

Microsoft Excel

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)

Celgene Corp., ROA, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)

Microsoft Excel

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Industry (Health Care)

Celgene Corp., ROA, long-term trends, comparison to industry (health care)

Microsoft Excel

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).